MedTrace Logo

Anxiety Control by Erythrina Mulungu

NCT01948622 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-09-23

No results posted yet for this study

Summary

This study evaluated the effectiveness of the Erythrina mulungu in controlling anxiety in patients undergoing bilateral extraction of asymptomatic, impacted mandibular third molars.

Conditions

  • Dental Anxiety
  • Impacted Third Molar Tooth

Interventions

DRUG

Mulungu

500 mg/single dose/1 hour before dental surgery

DRUG

Placebo

500 mg/single dose/1 hour before dental surgery

Sponsors & Collaborators

  • University of Campinas, Brazil

    collaborator OTHER

  • Liane Maciel de Almeida Souza

    lead OTHER

Principal Investigators

  • Liane M Souza, PhD · Federal University of Sergipe

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-06-30
Completion
2012-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01948622 on ClinicalTrials.gov